Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312520 | 1.00 | AOC3 (0.53) | AOC3TAAR1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL17976247 | 1.00 | AOC3 (0.53) | AOC3TAAR1L3MBTL1ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL4935607 | 0.98 | AOC3 (0.51) | AOC3TAAR1L3MBTL1ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL14862618 | 0.98 | AOC3 (0.51) | AOC3TAAR1L3MBTL1ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL15264351 | 0.98 | AOC3 (0.51) | AOC3TAAR1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL19791997 | 0.86 | AOC3 (0.50) | AOC3TAAR1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL1473114 | 0.85 | AOC3 (0.53) | AOC3TAAR1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL8514631 | 0.84 | AOC3 (0.55) | AOC3TAAR1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL12262611 | 0.84 | TP53 (0.55) | ALDH1A1CYP3A4 | |
| SCHEMBL18793771 | 0.84 | AOC3 (0.55) | AOC3TAAR1L3MBTL1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| CN-108929263-B | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |
| CN-111108092-A | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-05-05 | — | — | CN | disclosed |
| CN-107080747-A | Glucosylceramide synthase inhibitor | 建新公司 | 2017-08-22 | — | — | CN | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
| US-9359372-B2 | Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20150210711-A1 | HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2015-07-30 | — | — | US | disclosed |
| US-9090651-B2 | Helix 12 directed pharmaceutical products | ENDORECHERCHE, INC. (CA) | 2015-07-28 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| US-20050250749-A1 | Helix 12 directed pharmaceutical products | ENDORECHERCHE, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050187211-A1 | N-arylsalkyl-carboxamide compositions and methods | WEI EDWARD T (US) | 2005-08-25 | — | — | US | disclosed |
| US-20040143009-A1 | Amines, uses thereof | L'OREAL (FR) | 2004-07-22 | — | — | US | disclosed |
| US-6093851-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-0735018-B1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL CO (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5739401-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0735018-A1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250749-A1 | Helix 12 directed pharmaceutical products | SHBG, AR, NR5A1 | AOC3 4493/4885TAAR1 4592/4885L3MBTL1 3856/4885 |
| US-20050187211-A1 | N-arylsalkyl-carboxamide compositions and methods | OPRL1, TRPV1, TRPA1 | AOC3 2113/4885TAAR1 535/4885L3MBTL1 4475/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | AOC3 1606/4885TAAR1 518/4885L3MBTL1 3459/4885 |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | AOC3 730/4885TAAR1 2815/4885L3MBTL1 1037/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | AOC3 431/4885TAAR1 2895/4885L3MBTL1 3626/4885 |
| US-20150210711-A1 | HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | HTR5A, HTR1A, HTR2C | AOC3 2800/4885TAAR1 56/4885L3MBTL1 4019/4885 |
| US-20040143009-A1 | Amines, uses thereof | COL14A1, FBL, CUTA | AOC3 150/4885TAAR1 398/4885L3MBTL1 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.